Isg20l2 suppresses bortezomib anti-myeloma activity by attenuating bortezomib binding to psmb5

HIGHLIGHTS

• who: Zheng yuhuan and Huang Jingcao from the China Hospital Sichuan University have published the Article: ISG20L2 Suppresses Bortezomib Anti-Myeloma Activity by Attenuating Bortezomib Binding to PSMB5, in the Journal: (JOURNAL)
• what: The authors demonstrated the role of interferon-stimulated 20 kD exonuclease-like 2 (ISG20L2) in MM PI resistance. The authors show that ISG20L2 confers BTZ resistance on MM cells via a novel mechanism. The authors showed that a high level of ISG20L2 prevented BTZ from binding to its anti-MM target PSMB5.
• how: The authors identified interferon-stimulated 20 kD . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.